Last reviewed · How we verify

MBI 226 — Competitive Intelligence Brief

MBI 226 (MBI 226) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MBI 226 (MBI 226) — BioWest Therapeutics Inc. MBI 226 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to enhance anti-tumor immunity or reduce pathological inflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MBI 226 TARGET MBI 226 BioWest Therapeutics Inc phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MBI 226 — Competitive Intelligence Brief. https://druglandscape.com/ci/mbi-226. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: